Study to Evaluate the Effect of the Smart Care-diabetes Management System on Subjects With Diabetes
- Conditions
- Diabetes Mellitus
- Interventions
- Other: SMARTCARE service
- Registration Number
- NCT01505036
- Lead Sponsor
- SK Telecom Consortium
- Brief Summary
SMARTCARE-diabetes management system' to evaluate the long-term effects on patients with diabetes.
- Detailed Description
Primary Outcome Measure: To see if there's any change in HbA1C at Visit 6 (12M) compared Visit 2 (baseline) within each group and between the two groups.
All statistical analysis will progress through the SAS (Version 9.1). statistical test's significance level is 0.05. The principle is two-sided test.
Secondary Outcome Measures :
To see if there's any change in HbA1C at each Visit (Visit 3 - Visit 6) compared Visit 2 (baseline) within each group and between the two groups.
Add a Secondary Outcome Measure:
Treatment satisfaction (DTSQ, Diabetes Treatment Satisfaction Questionnaire): To see if there's any change in treatment satisfaction scores compared Visit 2 (baseline) within each group and between the two groups.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 554
- Type 2 diabetes
- At least 1 year after being diagnosed with Type 2 diabetes
- 7.0% ≤ HbA1c ≤ 10.0%
- Agreed to participate voluntarily in the study
- Severe chronic disease
- Diabetes mellitus complications
- Severe renal disease; Serum creatinin > 1.5(men), > 1.4 (women)
- Severe liver disease or AST, ALT ≥ 2.5 x ULN
- Known not to be taking medication reliably 3 months before the screening visit
- Insulin pump user
- Being registered for other clinical research or are planning to participate in other clinical researches during this study
- Pregnant woman
- Illiterate
- Being assessed irrelevant by the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SMARTCARE service SMARTCARE service U-Health service
- Primary Outcome Measures
Name Time Method Rate of patients who attain,Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months. 0 to 12 months Rate of patients who attain, Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.
- Secondary Outcome Measures
Name Time Method Change in Hemoglobin A1C at visit 3,4,6 from baseline 0 to 12 months Change in Hemoglobin A1C at Visit3,4,6 from baseline. Reduce Hemoglobin A1c after study
change in QOL(Quality of life) 0 to 12 months Change in QOL(Quality of life) at Visit 6 from baseline.
Treatment satisfaction(DTSQ, Diabetes Treatment Satisfaction Questionnaire) 0 to 12 months change in Treatment satisfaction(DTSQ, Diabetes Treatment Satisfaction Questionnaire) at Visit 6 from baseline.
Changes in lipid profile at Visit 4 and 6 from baseline. 0 to 12 months Changes in lipid profile at visit 4 and 6 from baseline. Reduction of lipid profile
Changes in body weight 0 to 12 months Changes in body weight at each visit(visit 3,4,5,6) from baseline during 12 months. Reduction of body weight
Changes in Waist Circumference(WC) 0 to 12 months Changes in Waist Circumference(WC) at each visit(visit 3,4,5,6) from baseline during 12 months.
Reduction of Waist Circumference(WC)Changes in Blood Pressure 0 to 12 months Changes in Blood Pressure at each visit(visit 3,4,5,6) from baseline during 12 months.
Changes in mean Blood Pressure
Trial Locations
- Locations (1)
Medicrostar
🇰🇷Seoul, Korea, Republic of